Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

We now know that cancer is many different diseases, with great variation even within a
single histological subtype. With the current emphasis on developing personalized …

Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of
patients with colorectal cancer will have metastatic disease at the time of initial diagnosis …

The past few decades have witnessed a tremendous progress in understanding the biology
of cancer, which has led to more comprehensive approaches for global gene expression …

Vascular endothelial growth factors (VEGFs) are the key regulators of vasculogenesis in
normal and oncological development. VEGF-A is the most studied angiogenic factor …

Abstract Background The phase III RAISE trial (NCT01183780) demonstrated that the
vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Colorectal tumors have been classified based on histologic factors, genetic factors, and
consensus molecular subtypes, all of which affect the tumor microenvironment. Elements of …

Blood vessels and lymphatic vessels are located in many tissues and organs throughout the
body, and play important roles in a wide variety of prevalent diseases in humans. Vascular …